CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Emtricitabine / Tenofovir Disoproxil Oral Tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03771638
NCT03771638Phase 4Completed

DOT Diary Longitudinal Pilot: A Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men

Public Health Foundation Enterprises, Inc.·interventional·Posted Dec 11, 2018·Updated Jul 3, 2025

In Brief

A Phase 4 clinical trial evaluating Emtricitabine / Tenofovir Disoproxil Oral Tablet and DOT Diary mobile app for Adherence, Medication and 3 related conditions. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies. DOT Diary reminds people when it is time to take their medication, and uses motion-sensing technology to visually and automatically confirm the pill was swallowed. The goal of this study is to assess the impact of the app on adherence to HIV pre-exposure prophylaxis (PrEP) for the prevention of HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 11, 2018
Enrollment StartFeb 1, 2019
Primary CompletionApr 21, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.6 years ago

Interventions

Emtricitabine / Tenofovir Disoproxil Oral Tabletdrug

Open label daily emtricitabine/tenofovir disoproxil oral tablet

DOT Diary mobile appother

DOT Diary mobile application for tracking medication adherence and sexual activities.